Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19 Post author: Post published:October 24, 2023 Post category:uncategorized Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. You Might Also Like Polygenic risk score shows potential to predict survival outcomes in breast cancer patients June 2, 2024 Two NIAID grants will support research on impacts of climate change on HIV-related health outcomes October 18, 2023 Complete revascularization proves effective for older STEMI patients in first 4 years September 2, 2024
Polygenic risk score shows potential to predict survival outcomes in breast cancer patients June 2, 2024
Two NIAID grants will support research on impacts of climate change on HIV-related health outcomes October 18, 2023
Complete revascularization proves effective for older STEMI patients in first 4 years September 2, 2024